Louisville, United States
GlobeImmune, Inc. is a *biopharmaceutical* company founded in 1995 in the United States. The company focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen ® platform. Tarmogens activate the immune system by stimulating T cells that destroy infected or malignant cells, presenting a promising alternative to traditional vaccines. GlobeImmune currently has four Tarmogen product candidates in clinical evaluation for infectious diseases and multiple cancer indications.
The company's approach involves targeting specific intracellular and extracellular proteins that play a role in oncology and infectious diseases, addressing unmet medical needs. GlobeImmune has managed to advance the development of its product candidates through collaborations with biopharmaceutical companies and research institutions. Notably, the company has two strategic collaborations with Gilead Sciences, Inc., and Celgene Corporation, involving licensing product candidates for the treatment of chronic hepatitis B virus infection and certain oncology product candidates.
GlobeImmune received over $60 million through these collaborations, with its last investment being a $391.73K Venture Round investment on 12 March 2014. These investments reflect the industry's confidence in the potential of GlobeImmune's innovative Tarmogen platform and its ability to address significant medical challenges in the field of biotechnology.
